SCHEMBL2552231

SCHEMBL2552231

COCCNc1cc(Br)ccc1[N+](=O)[O-]

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.68
MAPT P10636 9/20 0.62
ALDH1A1 P00352 5/20 0.62
HCAR3 P49019 1/20 0.55
RAB9A P51151 2/20 0.51
PTGER4 P35408 1/20 0.51
KMT2A Q03164 4/20 0.49
MEN1 O00255 3/20 0.49
POLB P06746 3/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TDP1 Q9NUW8 2/20 0.49
ALPG P10696 1/20 0.49
GAA P10253 1/20 0.47
KAT2B Q92831 1/20 0.46
HTR6 P50406 1/20 0.45
NPC1 O15118 1/20 0.45
HTT P42858 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
HPGD P15428 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29719258 1.00 LMNA (0.68) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL1046670 0.92 LMNA (0.57) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL15774731 0.89 LMNA (0.68) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL18496266 0.86 LMNA (0.50) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL29719483 0.86 LMNA (0.50) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL18496309 0.85 LMNA (0.49) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL29719210 0.85 LMNA (0.49) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL14616761 0.84 LMNA (0.70) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL1842548 0.84 HCAR3 (0.52) LMNAMAPTALDH1A1HCAR3RAB9A
SCHEMBL10576590 0.83 LMNA (0.68) LMNAMAPTALDH1A1HCAR3RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4539840-A1 KINASE MODULATORS AND METHODS OF USE THEREOF Neuron23, Inc. (US) 2025-04-23 EP disclosed
US-20240425481-A1 SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS EPIGENETIX, INC. 2024-12-26 US disclosed
WO-2023244788-A9 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2024-09-12 WO disclosed
US-11981657-B2 Substituted benzimidazoles, their preparation and their use as pharmaceuticals EPIGENETIX, INC. (US) 2024-05-14 US disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 US disclosed
WO-2023244788-A1 KINASE MODULATORS AND METHODS OF USE THEREOF NEURON23, INC. (US) 2023-12-21 WO disclosed
US-11731966-B2 Compounds and their methods of use PRAXIS PRECISION MEDICINES, INC. (US) 2023-08-22 US disclosed
US-11731966-B2 Compounds and their methods of use PRAXIS PRECISION MEDICINES, INC. (US) 2023-08-22 US disclosed
US-20230120413-A1 SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS NEOMED INSTITUTE (CA) 2023-04-20 US disclosed
EP-2552208-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS Glaxo Group Limited (GB) 2013-02-06 EP disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 US disclosed
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-17 US disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 WO disclosed
WO-2011123609-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 2011-10-06 WO disclosed
US-20060247233-A1 Thiazoles inhibitors of the alk-5 receptor SMITHKLINE BEECHAM CORPORATION 2006-11-02 US disclosed
EP-1660494-A2 THIAZOLES AS INHIBITORS OF THE ALK-5 RECEPTOR SMITHKLINE BEECHAM CORPORATION (US) 2006-05-31 EP disclosed
EP-1656367-A1 4- (HETEROCYCLYL- FUSED PHENYL)- 3- (PHENYL OR PYRID -2- YL) PYRAZOLES AS INHIBITORS OF THE ALK-5- RECEPTOR SmithKline Beecham Corporation (US) 2006-05-17 EP disclosed
WO-2004111036-A1 4- (HETEROCYCLYL- FUSED PHENYL)- 3- (PHENYL OR PYRID -2- YL) PYRAZOLES AS INHIBITORS OF THE ALK-5- RECEPTOR SMITHKLINE BEECHAM CORPORATION (US) 2004-12-23 WO disclosed
WO-2004111046-A2 THIAZOLES AS INHIBITORS OF THE ALK- 5 RECEPTOR SMITHKLINE BEECHAM CORPORATION (US) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731966-B2 Compounds and their methods of use SCN1A, SCN3A, SCN1B LMNA 688/4885MAPT 670/4885ALDH1A1 916/4885
US-20230120413-A1 SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS BRD3, BRDT, BRD4 LMNA 1886/4885MAPT 2018/4885ALDH1A1 1795/4885
US-20060247233-A1 Thiazoles inhibitors of the alk-5 receptor SMAD3, ALK, SMAD2 LMNA 1321/4885MAPT 982/4885ALDH1A1 2574/4885
US-11981657-B2 Substituted benzimidazoles, their preparation and their use as pharmaceuticals BRD3, BRDT, BRD4 LMNA 1886/4885MAPT 2018/4885ALDH1A1 1795/4885
US-20240425481-A1 SUBSTITUTED BENZIMIDAZOLES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS BRD3, BRDT, BRD4 LMNA 1886/4885MAPT 2018/4885ALDH1A1 1795/4885
US-20130018039-A1 IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS MAP3K19, MAP3K20, MAP3K3 LMNA 2804/4885MAPT 2704/4885ALDH1A1 2664/4885
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, JAK1, JAK3 LMNA 4294/4885MAPT 2656/4885ALDH1A1 4807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.